Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

Autor: Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, Di Bona G, Lee S, Henriksen JH, Ruiz del Arbol L, Angeli P, Garcia Tsao G, Gülberg V, Guevara M, Moreau R, Ortega R, Kamath P, Moore K, Mullen K, Sanyal A, Blendis L, Terg R., BERNARDI, MAURO

Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease, occurring mainly in patients with advanced cirrhosis and ascites, who have marked circulatory dysfunction,1 as well as in patients with acute liver failure.2 In spite of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::791e453345d6191d986d7103d1bf72d2
https://doi.org/10.1136/gut.2006.107789

Telaprevir for previously untreated chronic hepatitis C virus infection

Autor: Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., ADVANCE Study Team: Gadano A., Terg R., Bell S., Cheng W., Crawford D., Dore G., MacDonald G., Roberts S., Gschwantler M., Laferl H., Maieron A., Heathcote J., Kaita K., Myers R., Sherman M., Yoshida E., Barange K., Couzigou P., Pawlotsky J. M., Pol S., Serfaty L., Trépo C., Zarski J. P., Berg T., Buggisch P., Diepolder H., Goeser T., Mauss S., Rasenack J., Schmidt W., Wedemeyer H., Baruch Y., Ben Ari Z., Maor Y., Safadi R., Zuckerman E., Colombo M., Baka Cwierz B., Gladysz A., Janczewska Kazek E., Jablkowski M., Krycka W., Diago M., Esteban Mur R., Sanchez Tapias J., Brown A., Fox R., Afdhal N., Arora S., Bennett M., Bernstein D., Bloomer J., Bochan M., Bonkovsky H., Brady C., Brown R., Bzowej N., Cochran J., Chasen R., Davis G., De Jesus E., Di Bisceglie A., Dienstag J., Dieterich D., Etzkorn K., Everson G., Fried M., Freilich B., Ghalib R., Gitlin N., Godofsky E., Gordon S., Hassanein T., Jacobson I., Javadi F., Jonas M., Kilby A., Kwo P., Lawitz E., Lebovics E., Lee W., Luketic V., Maillard M., Monto A., Morgan T., Min A., Murphy M., Nelson D., Northup P., Nyberg L., Pockros P., Poordad F., Poulos J., Reddy R., Rodriguez Torres M., Satyanarayana R., Schiff E., Schwartz H., Shaikh O., Sheikh M., Sherman K., Smith J., Strohecker J., Sulkowski M., Szabo G., Te H., Terrault N., Tsai N., Vargas H., Vierling J., Wruble L., Younossi Z., Zein N., ANDREONE, PIETRO

A B S T R AC T Background In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon–ribavirin, as compared with peginterferon–ribavirin alone, has shown improved efficacy, with poten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052a883adee96e1a0f587feb78d8287d
http://hdl.handle.net/11585/129215

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program

Autor: Poynard, T., Mona Munteanu, Colombo, M., Bruix, J., Schiff, E., Terg, R., Flamm, S., Moreno-Otero, R., Carrilho, F., Schmidt, W., Berg, T., Mcgarrity, T., Heathcote, Ej, Gonçales, F., Diago, M., Craxi, A., Silva, M., Boparai, N., Griffel, L., Burroughs, M., Brass, C., Albrecht, J.

Publikováno v: BASE-Bielefeld Academic Search Engine

EPIC-3 is a prospective, international study that has demonstrated the efficacy of PEG-IFN alfa-2b plus weight-based ribavirin in patients with chronic hepatitis C and significant fibrosis who previously failed any interferon-alfa/ribavirin therapy.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a7e7086b37b933d9a03db0b8521f67c7
http://hdl.handle.net/10447/73857

Long-term follow-up of patients treated with daclatasvir-based regimens in phase 2 and 3 studies

Autor: Reddy, K. R., Pol, S., Thuluvath, P. J., Kumada, H., Toyota, J., Chayama, K., Levin, J. M., Lawitz, E., Gadano, A., Ghesquiere, W., Gerken, Guido, Brunetto, M. R., Peng, C. Y., Terg, R. B., Silva, M. O., Strasser, S. I., Heo, J., McPhee, F., Liu, Z. H., Linaberry, M., Hughes, E. A., Noviello, S.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=unidue___bib::fd5bfbde5c83edf2b54976f8492ea1e5

Interferon-alpha 2b combined with daily ketoprofen administration improves virological response in chronic hepatitis C: a prospective and randomised trial

Autor: Munne Ms, Diego Martin Flichman, Podestá A, Terg R, Levi D, Alberto Muñoz, Cabanne A, Maria Bartellini, Gorín Jm, González J

Publikováno v: Gut. 46(3)

BACKGROUND—Less than 15% of patients with chronic hepatitis C show a sustained virological response to interferon treatment. AIM—To evaluate the efficacy and safety of different doses of ketoprofen combined with interferon-α 2b in the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55e9a4c8ceacb66faf690a99d1229efe
https://pubmed.ncbi.nlm.nih.gov/10673287